Three-Year Switch Exclusivity Included In Amended EU Drug Legislation
This article was originally published in The Tan Sheet
Executive Summary
Three years of data exclusivity for Rx-to-OTC switch candidates and new indications of approved medicinal products would be available to European drug marketers under legislation currently making its way through the European regulatory process
You may also be interested in...
Should Unqualified Health Claims Sound Less Tentative? FDA Seeks Input
FDA is requesting additional comments on whether the words "may" or "might" should be removed from unqualified health claims to avoid consumer confusion about the science substantiating the claim
Should Unqualified Health Claims Sound Less Tentative? FDA Seeks Input
FDA is requesting additional comments on whether the words "may" or "might" should be removed from unqualified health claims to avoid consumer confusion about the science substantiating the claim
Should Unqualified Health Claims Sound Less Tentative? FDA Seeks Input
FDA is requesting additional comments on whether the words "may" or "might" should be removed from unqualified health claims to avoid consumer confusion about the science substantiating the claim